Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 26, 2026.

Sign in

Medical Properties Trust Inc

MPT NYSE Real Estate Investment Trusts Financials FY2016–FY2025

Medical Properties Trust Inc had $972M of revenue in fiscal 2025, down 2.4% on the year before. Over five years, revenue changed βˆ’4.9% a year on average.

Add to portfolio Download report

Last close Β· Oct 23, 2026

$2.70

0.4%

What Medical Properties Trust Inc does

MPT Β· Real Estate Investment Trusts

From its latest annual report

No business description yet.

Filing details

Legal name
MEDICAL PROPERTIES TRUST INC
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Feb 26, 2026
Accession Β· CIK
0001193125-26-073587 Β· 0001287865

Earnings calendar Β· Medical Properties Trust Inc

Every quarter, companies publish how much they sold and earned. These are the days Medical Properties Trust Inc did it, and the next one. Share prices often move a lot on those days.

Next results

October 29, 2026

Thursday Β· in 3 days

Time
Before the market opens
Covers
Period ended Sep 30, 2026
Expected EPS
$0.13
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Aug 10, 2026 Period ended Jun 30, 2026 Before the market opens 8-K β†—
Apr 30, 2026 Q1 '26 Before the market opens 8-K β†—
Feb 19, 2026 Q4 '25 Before the market opens 8-K β†—
Oct 30, 2025 Q3 '25 Before the market opens 8-K β†—
Jul 31, 2025 Q2 '25 Before the market opens 8-K β†—
May 1, 2025 Q1 '25 Before the market opens 8-K β†—
Feb 27, 2025 Q4 '24 Before the market opens 8-K β†—
Nov 7, 2024 Q3 '24 Before the market opens 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Medical Properties Trust Inc’s latest annual report (fiscal 2025). Here is what stands out:

3 to watch

1.Sales and profit

See section β†’
  • Medical Properties Trust Inc had $972M of revenue in fiscal 2025, down 2.4% on the year before. Over five years, revenue changed βˆ’4.9% a year on average.
  • Medical Properties Trust Inc lost $277M in fiscal 2025.

2.Cash and shareholders

See section β†’
  • Medical Properties Trust Inc returned $23.4M to shareholders in fiscal 2025. The diluted share count rose 0.1%.
  • In the last 12 months, insiders bought $0.0M and sold $0.3M of shares on the open market.

Medical Properties Trust Inc in 30 seconds

Good So-so Weak

Weak

Are sales growing?

βˆ’2.4%

No. Sales fell 2.4% last year.

Weak

Does it make a profit?

βˆ’28.5%

No. It lost money last year.

Weak

How healthy are the accounts?

3 / 8

Weak. It passes 3 of 8 health tests.

For information

How is the share priced?

β€”

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$1.6B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$0.21 EPS (TTM)

Revenue

Total sales reported in the income statement.

KIRA Β· Medical Properties Trust Inc had $972M of revenue in fiscal 2025, down 2.4% on the year before. Over five years, revenue changed βˆ’4.9% a year on average.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Medical Properties Trust Inc lost $277M in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

KIRA Β· Medical Properties Trust Inc had $972M of revenue in fiscal 2025, down 2.4% on the year before. Over five years, revenue changed βˆ’4.9% a year on average.

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Medical Properties Trust Inc lost $277M in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

KIRA Β· Medical Properties Trust Inc returned $23.4M to shareholders in fiscal 2025. The diluted share count rose 0.1%.

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· In the last 12 months, insiders bought $0.0M and sold $0.3M of shares on the open market.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.0M

1 insider

Sold, 12 months

$0.3M

2 insiders

Of sales under plans

0%

$0.0M

DateInsiderTradeSharesPriceValueFiling
Aug 20, 2026 James Kevin HannaSenior VP, Controller & CAO Bought 2,300 $4.15 $0.0M Form 4
Dec 15, 2025 Rosa Handley HooperSVP of Operations Sold 2,000 $5.00 $0.0M Form 4
Nov 19, 2025 Michael G StewartDirector Sold 59,000 $5.02 $0.3M Form 4

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

KIRA Β· Medical Properties Trust Inc owes $9.2B more than it holds in cash.

Cash, debt and the ratios that show how comfortably Medical Properties Trust Inc can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $459M$236M$250M$332M$541M
Debt incl. finance leases $11.3B$10.3B$10.1B$8.9B$9.7B
Debt / equity 1.3x1.2x1.3x1.8x2.1x
Total assets $20.5B$19.7B$18.3B$14.3B$15.0B
Total liabilities $12.1B$11.1B$10.7B$9.5B$10.4B
Shareholders' equity $8.4B$8.6B$7.6B$4.8B$4.6B
Net debt (βˆ’ = net cash) $10.8B$10.0B$9.8B$8.5B$9.2B

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Medical Properties Trust Inc passes 3 of 8 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ• βœ• βœ•
Cash from operations is positive βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Return on assets rose β€” βœ• βœ“ βœ• βœ• βœ“ βœ“ βœ• βœ• βœ“
Cash from operations exceeds net income βœ“ βœ“ βœ• βœ“ βœ“ βœ“ βœ• βœ“ βœ“ βœ“
Debt fell relative to assets β€” βœ• βœ“ βœ• βœ• βœ• βœ“ βœ• βœ• βœ•
Current ratio rose β€” β€” β€” β€” β€” β€” β€” β€” β€” β€”
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ• βœ• βœ“ βœ• βœ•
Gross margin rose β€” β€” β€” βœ• βœ“ βœ• βœ• βœ• βœ“ βœ•
Revenue rose relative to assets β€” βœ• βœ“ βœ• βœ“ βœ“ βœ“ βœ• βœ“ βœ•
F-score β€” / 33 / 75 / 73 / 85 / 85 / 85 / 83 / 84 / 83 / 8
Accruals ratio βˆ’0.6%βˆ’0.9%6.4%βˆ’1.0%βˆ’1.2%βˆ’0.8%0.8%βˆ’5.6%βˆ’16.3%βˆ’3.5%
Altman Z'' β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”

All figures

Every number, year by year.

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $541M $705M $785M $854M $1.2B $1.5B $1.5B $872M $996M $972M
Gross profit β€” β€” $700M $686M $1.2B $1.4B $1.4B $762M $921M $882M
Operating income $342M $486M β€” β€” β€” β€” β€” β€” β€” β€”
Interest expense $160M $177M $223M $238M $329M $367M $359M $411M $418M $510M
Pretax income $219M $294M $1.0B $374M $463M $731M $960M βˆ’$687M βˆ’$2.4B βˆ’$237M
Income tax βˆ’$6.8M $2.7M $0.9M βˆ’$2.6M $31.1M $73.9M $55.9M βˆ’$131M $44.1M $38.6M
Net income $225M $290M $1.0B $375M $431M $656M $903M βˆ’$556M βˆ’$2.4B βˆ’$277M
Diluted EPS $0.86 $0.82 $2.76 $0.87 $0.81 $1.11 $1.50 βˆ’$0.93 βˆ’$4.02 βˆ’$0.46
Diluted shares 0.26B 0.35B 0.37B 0.43B 0.53B 0.59B 0.60B 0.60B 0.60B 0.60B
Cash flow
Cash from operations $264M $362M $449M $494M $618M $812M $739M $506M $245M $231M
Depreciation and amortization $97.6M $132M $141M $157M $276M $334M $346M $616M $454M $273M
Stock-based compensation $7.9M $9.9M $16.5M $32.2M $47.2M $52.1M $49.4M $33.3M $33.0M $25.7M
Share buybacks β€” β€” β€” β€” β€” β€” $17.9M β€” β€” $23.4M
Dividends and buybacks β€” β€” β€” β€” β€” β€” $17.9M β€” β€” $23.4M
Balance sheet
Cash and short-term investments $83.2M $171M $821M $1.5B $550M $459M $236M $250M $332M $541M
Total debt $2.9B $4.9B $4.0B $7.0B $8.9B $11.3B $10.3B $10.1B $8.8B $9.7B
Finance lease liabilities β€” β€” β€” $1.9M $1.9M $1.9M $1.9M $1.9M $1.9M $1.9M
Total assets $6.4B $9.0B $8.8B $14.5B $16.8B $20.5B $19.7B $18.3B $14.3B $15.0B
Total liabilities $3.2B $5.2B $4.3B $7.4B $9.5B $12.1B $11.1B $10.7B $9.5B $10.4B
Preferred stock β€” β€” β€” β€” β€” β€” β€” $0.0M β€” β€”
Shareholders' equity $3.2B $3.8B $4.5B $7.0B $7.3B $8.4B $8.6B $7.6B $4.8B $4.6B
Margins
Gross margin β€” β€” 89.3% 80.3% 97.6% 93.4% 89.1% 87.4% 92.6% 90.7%
Operating margin 63.1% 68.9% β€” β€” β€” β€” β€” β€” β€” β€”
EBITDA margin 81.2% 87.6% β€” β€” β€” β€” β€” β€” β€” β€”
Net margin 41.6% 41.1% 129.6% 43.9% 34.5% 42.5% 58.5% βˆ’63.8% βˆ’242.1% βˆ’28.5%
Returns
Return on capital 5.6% 5.6% β€” β€” β€” β€” β€” β€” β€” β€”
Return on equity 6.9% 8.2% 24.3% 6.5% 6.0% 8.3% 10.6% βˆ’6.9% βˆ’38.7% βˆ’5.9%
Return on assets 3.5% 3.8% 11.4% 3.2% 2.8% 3.5% 4.5% βˆ’2.9% βˆ’14.8% βˆ’1.9%
Return on tangible equity 6.9% 7.6% 22.4% 5.3% 5.9% 7.8% 10.5% βˆ’7.3% βˆ’49.9% βˆ’6.0%
Growth
Revenue growth β€” 30.2% 11.3% 8.9% 46.2% 23.6% βˆ’0.1% βˆ’43.5% 14.2% βˆ’2.4%
Net income growth β€” 28.8% 250.8% βˆ’63.1% 15.2% 52.1% 37.6% βˆ’161.7% β€” β€”
EPS growth β€” βˆ’4.7% 236.6% βˆ’68.5% βˆ’6.9% 37.0% 35.1% βˆ’162.0% β€” β€”
Share count change β€” 34.2% 4.5% 16.9% 23.9% 11.3% 1.5% βˆ’0.1% 0.3% 0.1%
Financial health
Net debt / EBITDA 6.4x 7.7x β€” β€” β€” β€” β€” β€” β€” β€”
Debt / equity 0.9x 1.3x 0.9x 1.0x 1.2x 1.3x 1.2x 1.3x 1.8x 2.1x
Interest coverage 2.1x 2.7x β€” β€” β€” β€” β€” β€” β€” β€”
Capital allocation
Stock comp / revenue 1.5% 1.4% 2.1% 3.8% 3.8% 3.4% 3.2% 3.8% 3.3% 2.6%
Quality scores
Piotroski F-score β€” 3.0 5.0 3.0 5.0 5.0 5.0 3.0 4.0 3.0
Accruals ratio βˆ’0.6% βˆ’0.9% 6.4% βˆ’1.0% βˆ’1.2% βˆ’0.8% 0.8% βˆ’5.6% βˆ’16.3% βˆ’3.5%

Source: SEC EDGAR XBRL filings (CIK 0001287865). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open